AI Article Synopsis

  • Alzheimer's disease is a condition marked by cognitive and functional declines, and the study examined the effects of tilavonemab on these declines using the Clinical Dementia Rating (CDR) scale.
  • Researchers used longitudinal Item Response Theory (IRT) models to analyze changes in early-stage AD patients, finding that cognitive decline was faster than functional decline, and tilavonemab did not provide significant benefits.
  • The study highlighted a significant relationship between baseline severities and their progression rates, indicating that cognitive and functional declines in AD are interconnected, and suggested the usefulness of multidimensional IRT models for understanding disease progression.

Article Abstract

Introduction: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by declines in cognitive and functional severities. This research utilized the Clinical Dementia Rating (CDR) to assess the influence of tilavonemab on these deteriorations.

Methods: Longitudinal Item Response Theory (IRT) models were employed to analyze CDR domains in early-stage AD patients. Both unidimensional and multidimensional models were contrasted to elucidate the trajectories of cognitive and functional severities.

Results: We observed significant temporal increases in both cognitive and functional severities, with the cognitive severity deteriorating at a quicker rate. Tilavonemab did not demonstrate a statistically significant effect on the progression in either severity. Furthermore, a significant positive association was identified between the baselines and progression rates of both severities.

Discussion: While tilavonemab failed to mitigate impairment progression, our multidimensional IRT analysis illuminated the interconnected progression of cognitive and functional declines in AD, suggesting a comprehensive perspective on disease trajectories.

Highlights: Utilized longitudinal Item Response Theory (IRT) models to analyze the Clinical Dementia Rating (CDR) domains in early-stage Alzheimer's disease (AD) patients, comparing unidimensional and multidimensional models.Observed significant temporal increases in both cognitive and functional severities, with cognitive severity deteriorating at a faster rate, while tilavonemab showed no statistically significant effect on either domain's progression.Found a significant positive association between the baseline severities and their progression rates, indicating interconnected progression patterns of cognitive and functional declines in AD.Introduced the application of multidimensional longitudinal IRT models to provide a comprehensive perspective on the trajectories of cognitive and functional severities in early AD, suggesting new avenues for future research including the inclusion of time-dependent random effects and data-driven IRT models.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11148533PMC
http://dx.doi.org/10.1002/trc2.12471DOI Listing

Publication Analysis

Top Keywords

cognitive functional
28
functional severities
16
irt models
16
alzheimer's disease
12
longitudinal item
12
item response
12
response theory
12
cognitive
9
clinical dementia
8
dementia rating
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!